“Tilts, Spins, and Tears: Approaches to head tilts in rabbits” will be presented by Dr Madonna Livingstone BVMS MRCVS, who will discuss a range of approaches, diagnostic and treatment options for rabbits presenting with head tilt symptoms.
Madonna has over 20 years experience in veterinary practice, and as Head Vet and Head of Exotics at Ark Veterinary Clinics Ltd, she speaks widely on exotic animal medicine and surgery.
She also delivers clinical exotic lectures and practicals at Glasgow Vet School, holds a diploma in parrot behaviour and is publishing a textbook on rabbits and small exotic mammals this year.
The webinar aims to help veterinary staff to recognise the differential diagnosis list, know how to achieve a diagnosis, or most likely diagnosis within a restricted budget; know the available treatment options; and know how to manage owners’ expectations.
https://horiba.link/head-tilts-in-rabbits
The decision was made after Council heard increasing reports that practices have not been keeping records of POM-V parasiticide prescriptions within patient records as has always been required by the VMD.
This created a bit of a problem when the new 'under care' guidance came into force at the start of this month, which requires that veterinary surgeons must perform a physical examination as part of their initial clinical assessment of an animal before prescribing POM-V anti-parasitics.
Failing a record of an existing prescription, that would have meant re-examining large numbers of animals at a time when resources in the profession are already stretched.
RCVS President, Sue Paterson, said: “While it has been both surprising and disappointing to learn of such widespread non-compliance with legislation that has been in place for many years, Council decided to postpone the implementation of this one aspect of our new under care guidance to allow practices additional time to bring their prescribing protocols into line."
The delayed implementation date of 12 January 2024 relates only to the prescription of POM-V anti-parasitics.
The rest of the new under care guidance remains in effect from 1 September 2023
The company says the webinars will equip veterinary professionals with strategies to strengthen wellbeing both individually and for practice teams.
Lauren Hayes, Scientific and Regulatory Affairs Manager at Royal Canin, said: “Working within clinical veterinary practice can be hugely rewarding and enriching, but it cannot be ignored that our industry also has its challenges.
"Veterinary surgeons have a significantly higher risk of suicide compared to the general population and mental health issues around work life balance and compassion fatigue are widespread.
"Through our webinar series, we hope to encourage conversations around mental health and help provide advice directly from leading experts.”
The one-hour webinars will take place at 7pm every Wednesday throughout September.
https://vetportal.royalcanin.co.uk/news/new-veterinary-professional-health-webinar-series/
Pooch & Mutt has 20x 40-day trials of its new joint & bone supplement, Mobile Bones Concentrate, to give away to veterinary professionals.
Guy Blaskey from Pooch & Mutt said: "At The London Vet Show vets and vet nurses told us that they loved the new Mobile Bones Concentrate because at just £9.99 per month it costs less than other joint supplements (whilst having the same high quality ingredients), it takes up a very small amount of shelf space and it doesn't involve the client having to either change their dog's food or stuff pills down their dog's throat."
In response to requests from vets and vet nurses to try the new joint supplement, Pooch & Mutt have set up a dedicated website at www.jointsupplementfordogs.com where you can apply from one of twenty 40 day trials.
Guy continued, "We did not want to simply send samples out to everyone. By setting up the site we can choose a variety of dogs from different breed and with different conditions to send a full 40-day trial to. We hope to get regular feedback from the vets, vet nurses and dog owners involved in the trial and publish it on http://www.jointsupplementfordogs.com/ for everyone else to see."
The trials are available to all veterinary professionals and can be for their own dogs, or dogs belonging to their clients.
An online presentation by Danielle Gunn-Moore, Professor of Feline Medicine at the Royal (Dick) School of Veterinary Studies in Edinburgh, has been launched by Dechra Veterinary Products as part of its Dechra Academy training suite.
During the presentation, Professor Gunn-Moore uses a case study approach to discuss all aspects of the condition from diagnosis through to its treatment, management and on-going monitoring. She reminds viewers that an individual approach must be taken in treating affected cats as the clinical signs can be subtle and starting treatment with the lowest possible dose of anti-thyroid medication is likely to prove physiologically beneficial.
"The study I've recently been involved in showed that the treatment of hyperthyroid cats can result in iatrogenic hypothyroidism*. Hypothyroid cats are significantly more likely to develop azotaemia than euthyroid cats - and hypothyroid cats that developed azotaemia in the study had significantly shorter survival times*.
"The message for practitioners is that there is no 'standard recipe' in treating hyperthyroidism. The clinical signs aren't always obvious and it's important to check for concurrent heart and kidney disease. You then need to tailor treatment, starting with a low dose of medication and, if necessary, increasing it by the smallest increments possible."
To watch Professor Gunn-Moore's presentation, visit www.dechra.co.uk/hyperthyroidism.
Reference:* Williams, T. et al (2010) JVIM 24: 1086-1092
Dechra Veterinary Products has launched Buprenodale, an opioid analgesic for cats, dogs and horses presented in a 10ml multi-dose vial.
Carol Morgan, Brand Manager said: "Following on from the introduction of Comfortan and Anesketin, our Buprenodale Multidose, 0.3 mg/ml solution for injection for dogs, cats and horses, is the latest addition to the portfolio.
"The active substance in Buprenodale is buprenorphine, the most commonly used opioid analgesic in small animal practice in the UK.
"Buprenodale Multidose joins a portfolio of Dechra products covering a wide range of species, different levels of analgesic efficacy and duration of action.
"The product is now available in a 10 ml multidose vial. It is suitable for post-operative analgesia in dogs and cats; post operative analgesia, in combination with sedation, in horses and potentiation of the sedative effects of centrally acting agents in the dog and horse."
For more information www.dechra.co.uk .
At the outset of the hearing, Mr Kashiv, from Vets & Pets, Broxbourne, denied all aspects of the charges against him. During the course of the inquiry, some heads of charge were not pursued and some he admitted, leaving the remaining heads of charge to be determined.
The charges concerned the treatment of a Scottish Terrier, called Tanzy, whose owner, Mrs Greenhill, brought her in to see Mr Kashiv on 5 March 2015. Mrs Greenhill was concerned about blood in Tanzy’s urine and swellings in her mammary glands. After carrying out a cytopathology test, Mr Kashiv advised Mrs Greenhill that Tanzy would require surgery to remove the mammary glands. There were no further tests conducted, and no alternatives to surgery suggested.
On 13 March another veterinary surgeon at Vets & Pets therefore undertook a right-side mammary strip on Tanzy, discharging her the following day. On 17 March Mrs Greenhill brought Tanzy back in for a post-operative check and was seen by a locum veterinary surgeon, who found her to be in good condition.
On 20 March Mrs Greenhill then became concerned about Tanzy’s deteriorating condition and returned her to see Mr Kashiv. He admitted Tanzy for observation over the weekend but did not conduct any further tests at that stage, apart from radiography on 22 March. The hospitalisation records were of poor quality and substantially incomplete.
On 23 March Mr Kashiv then informed Mrs Greenhill that Tanzy could be discharged, although he recommended an MRI scan to assist in the diagnosis; this was declined on cost grounds. He did not however explain clearly to Mrs Greenhill that Tanzy’s prognosis was bleak, and did not give adequate home care instructions.
Tanzy continued to deteriorate, and on 24 March Mrs Greenhill took Tanzy to the RSPCA Harmsworth Hospital where a veterinary surgeon conducted tests which showed that Tanzy was in renal failure. The veterinary surgeon then called Mrs Greenhill and recommended that Tanzy was put to sleep, which was then performed in Mrs Greenhill’s presence.
The Committee found that Mr Kashiv had failed to conduct the necessary investigations when Tanzy was admitted from 20 to 23 March 2015, being satisfied that, by the time Tanzy had been hospitalised for a period of three days, it was mandatory for a blood test to have been performed, given her marked deterioration.
The Committee also found while Mr Kashiv did express his opinion that Tanzy’s prognosis was poor, he did not give the full explanation required in the circumstances of this case to enable Mrs Greenhill to understand fully the prognosis. The Committee also considered that Tanzy was not in a fit state to be discharged on 23 March 2015, and that he had failed to keep sufficiently clear and/or detailed and/or accurate records.
After full consideration, the Committee found that Mr Kashiv’s actions amounted to serious professional misconduct, and was satisfied that his actions fell far short of the conduct to be expected of a reasonably competent veterinary surgeon in respect of heads of charge 1, 2 and 3 but not 4.
Although it was concerned "about the culture of care in the practice, in particular not having in place proper protocols and procedures and without necessary support from properly trained staff", in deciding on appropriate sanction, the Committee was satisfied that there were "a number of serious misjudgements by Mr Kashiv in this case".
The Committee decided to postpone judgement for a period of two years, whilst recommending that Mr Kashiv agree to undertake a structured programme to benefit his clinical practice including a Personal Development Plan, mentoring, practice visits, additional CPD and regular reports to the Disciplinary Committee.
Non-compliance with these undertakings may result in the hearing being resumed at a date earlier than the two-year period.
Stuart Drummond, Chairing the Disciplinary Committee and speaking on its behalf, said: "The Committee considers that Mr Kashiv is a dedicated veterinary surgeon, as evidenced by the large number of testimonials, and that he provides a valuable service to the community, particularly with rescue animals.
"Nevertheless, the Committee considers that there were a number of fundamental failings in Mr Kashiv’s clinical competence which are required to be addressed during the period of postponement. For the reasons set out above the Committee considers that Mr Kashiv’s clinical practice will benefit from a structured programme over the period of postponement, whilst protecting the welfare of animals, maintaining public confidence in the profession and declaring and upholding proper standards of conduct."
For the full charges, findings and decisions, see: http://www.rcvs.org.uk/concerns/disciplinary-hearings/
The company announced last month that from 1st January next year, practices will have to order companion animal and ruminant products via either MWI or NVS (who will also fulfil the order), but will be invoiced direct by MSD.
Pig products will join aquaculture and poultry products to be supplied directly to customers by MSD Animal Health.
In its announcement, the company said that the new structure would allow the company to enhance the customer experience and more quickly adapt to changes in the market to better serve its customers.
VetSurgeon.org contacted the company for further clarification about how the customer experience would be improved.
The company explained that the two main benefits of the new structure concern price visibility and stock control.
A spokesperson for the company said: "Currently, customers may get a discount from us and separately a discount from wholesaler. With our new distribution model we will invoice monthly and all discounts will be on one invoice, so it will be easier to determine the actual price paid."
The spokesperson explained that with the old model, once stock was sold to wholesalers it would be allocated to customers, so there would be some held by MSD, some allocated and some in distribution: "The benefit of the new model is we will have full oversight of stock as it will be in our own warehouses or with distribution partners. If there are disruptions in the market, we will have better awareness of in market demand and we can allocate stock appropriately".
The course is aimed at veterinary professionals across Europe who want to advance their knowledge and diagnostic skills, progress their academic qualifications and gain recognition in their field.
The GPAdvCert in Small Animal Medicine is for veterinary surgeons who have already completed a General Practitioner Certificate in Small Animal Medicine (GPCertSAM) or a Postgraduate Certificate (PgC) in Small Animal Medicine.
Accredited by the European School of Veterinary Postgraduate Studies (ESVPS) and validated by Harper Adams University, the programme will be delivered in three, five-day blocks of training by globally recognised experts in three European training centres - Sheffield, UK; Porto, Portugal and Berlin, Germany. The programme includes a practical session in which delegates will perform an upper and lower gastrointestinal endoscopy under the guidance of their tutor.
David Babington MRCVS, Business Development Director of Improve International (pictured right), said: "Delegates attending our first GPAdvCert in Small Animal Medicine will enhance their skills and confidence in dealing with complex animal medicine cases. Each module will take their knowledge beyond Postgraduate Certificate level with more in-depth and advanced content covering topics as diverse as mycobacterial and ureteric disease. They will also learn how to design a detailed diagnostic plan and build an understanding of nuances in interpreting laboratory findings to enable them to manage cases requiring complex therapeutic management with confidence."
He added: "The qualification is a natural ‘next-step’ for veterinary surgeons wanting to further progress their knowledge of small animal internal medicine. It will help them to reduce the number of patients which are referred, retaining a higher level of income for their practice and will also provide them with skills which they can pass onto their team."
Improve says the successful achievement of the GPAdvCert will enable delegates to progress from a Postgraduate Certificate in Small Animal Medicine (or equivalent) to the Postgraduate Diploma in Advanced Veterinary Practice Sciences in the UK, which is awarded by Harper Adams University. This can, in turn, be used towards the award of a Masters Degree (MSc) in Advanced Veterinary Practice Sciences.
The company has launched a ‘Vet Show CPD hub’ (www.myelanco.co.uk/brand/lvshub) which, as the name suggests, hosts a variety of CPD presentations accompanied by competitions, including one in which you can win £250 Amazon vouchers.
The CPD hub also has information about the company's range of products, including Credelio, Neptra, Galliprant and Advocate.
From the 10th November, Elanco will also host a series of webinars in partnership with the London Vet Show (https://london.vetshow.com/elanco):
As a thank you, the first people to sign up to the webinars will also get an ‘Elanco Vet Show CPD at home’ box, with goodies to enjoy while tuning into the virtual event.
Tina Hunt, managing director of Elanco UK/Ireland, said: "2020 has been a year of incredible change, which has included our global acquisition of Bayer Animal Health. While we remain physically separated, it is important to us that we continue to engage with our veterinary friends and customers to maintain the sense of community that networking events can be so vital in nurturing.
"We also wanted to take this opportunity to recognise the commitment of veterinary professionals across the UK and thank you for your ongoing support and dedication at the forefront of animal care. Our entire team look forward to you joining us for three exciting webinars and to hosting you on our hub."
Ceva says the course is aimed at vets and nurses who want to build their confidence and take the lead in finding hypertension in cats in their clinic.
The course is hosted by Sarah Caney BVSc DSAM(Feline) MRCVS, one of the UK's leading specialists in feline medicine, and will cover things like finding out which cats need screening for feline hypertension, how to become confident in recommending a blood pressure check to owners, hints and tips on taking a reliable blood pressure measurement and handling cats calmly to reduce ‘situational hypertension’.
The course consists of four 30-minute recorded sessions including course notes and self-assessment questions for each module. Once completed, the delegate will receive a Hypertension Ambassador pin badge and a certificate for four hours’ CPD. The first 500 delegates to complete the course will be offered either a cat hide or an eye atlas.
The course can be completed online at any time. There are also weekly feline hypertension live sessions at 1pm, from Wednesday 4th March until Wednesday 25th March. They offer the opportunity for you to ask questions, but they're also recorded so you can watch them any time thereafter.
Suzanne Page BVSc MRCVS, cardio-nephrology-hypertension product manager at Ceva Animal Health, said: "Our HypertensionAmbassadors’ initiative will educate veterinary professionals on every aspect of feline hypertension to enable them to confidently talk to their clients about the condition, measure blood pressure in a cat-friendly way and offer advice on the different treatments available."
For more information, and to register, visit www.veterinarywebinars.com/feline-hypertension-ambassador.
Zoetis has announced that following a positive opinion from the Committee for Medicinal Products for Veterinary Use (CVMP), the European Commission has approved Apoquel (oclacitinib tablet) in the European Union for the treatment of pruritus associated with allergic dermatitis and the treatment of clinical manifestations of atopic dermatitis in dogs at least 12 months of age.
Developed by Zoetis, Apoquel is the first Janus kinase (JAK) inhibitor approved for veterinary use. The company says it inhibits the function of a variety of allergic, itch and pro-inflammatory cytokines dependent on JAK enzyme activity and thus stops the cycle of itch and inflammation occurring in skin allergies.
Michael Stegemann, Senior Director Global Development Organisation at Zoetis said: "Apoquel is a targeted treatment that specifically inhibits JAK-dependent cytokines involved in allergic skin disease in dogs. Its rapid anti-pruritic effect along with its anti-inflammatory properties provide fast relief to dogs. Relief from itch and inflammation is maintained in dogs receiving long-term treatment with Apoquel. This exciting innovation molecule offers quick, effective, and sustained itch relief; improves skin lesions continuously and can be used safely short or long-term."
Zoetis says that in clinical trials, Apoquel demonstrated safety and efficacy for the treatment of itch and resulted in improved skin lesions in dogs diagnosed with a number of allergic skin diseases as well as atopic dermatitis and treated either short or long term. The decrease in itch scores was observed by pet owners as soon as 24 hours after administration, the first observation time point, and itch continued to decrease compared to baseline until the end of the study. Skin lesions scores assessed by veterinary surgeons were significantly improved after one week and continued to improve long term during the studies (4 months). In these studies, the most common side effects observed in dogs treated with Apoquel were vomiting and diarrhea. Other reported side effects included lethargy, decreased or lack of appetite, skin irritation or infection, and ear irritation or infection.
Apoquel will be a POM-V treatment. Apoquel tablets, dosed at 0.4 to 0.6 mg/kg, are administered orally, twice daily for up to 14 days, and then administered once daily for maintenance therapy if medium to long term treatment is required, such as in dogs with seasonal skin allergy and atopic dermatitis.
Zoetis plans to make Apoquel available to veterinary surgeons in the European Union during 2014. Meantime, Zoetis says it will be working with vets on the new science and research findings around itch and canine allergic diseases. For more information, visit www.zoetis.com, www.itchcycle.com.
For the trial, the company has partnered with Pennard Vets in Kent, where they're using Google Glass to transmit what the practitioner sees straight to the consulting experts at VetCT.
The remote VetCT specialist is able to view and remotely record, zoom, adjust lighting, annotate and send images back for the wearer of the glasses to view.
They are also able to discuss the case live with team in the clinic.
As part of the trial, images streamed via the glasses are being compared against those shot on a higher resolution mobile phone.
Director and Innovation Lead at VetCT, Julien Labruyère said: “We have a tremendous resource of specialist knowledge and expertise within our global team, and are exploring new ways to maximise the potential benefits of real-time clinical mentoring, teaching and case support.
"This first step we have taken with Google Glass marks the start of an exciting journey to make smart glasses technology useful to help vets in practice."
Caroline Collins, Director at Pennard Vets, said: “Trialling the glasses has been a fascinating exercise. We’re now looking at cases where we could see the most benefit from real-time specialist feedback and hands-free capability. It could be a real game-changer in some situations, for example with remote guidance of patient examinations or complex procedures.”
To learn more about VetCT visit www.vet-ct.com.
However, when asked by VetSurgeon.org which audience - veterinary professionals, it's staff or the public - it was referring to, or what threats to safety and wellbeing were posed by X, the College refused point blank to answer.
So the real motivation remains unclear.
On the one hand, it could be a ridiculously over-sensitive move to protect its unknown audience from opinions that its staff find objectionable.
On the other hand, it could perfectly well be argued that short form social media reduces every discussion or debate to "I'm effing right and you're effing wrong", which is not appropriate for a scientific profession.
Equally, one could also argue that engaging in polarised debate online is not terribly good for one's wellbeing.
Or one could just argue that it's a terrible platform owned by a strangely meddlesome and interfering American.
However, given the College's strange refusal to expand on the reasons for its withdrawal, the first explanation seems more likely.
But who knows?
https://www.rcvs.org.uk/news-and-views/news/rcvs-statement-on-x-formerly-twitter/
MSD Animal Health (Merck in the US and Canada), has launched Finadyne (flunixin), the NSAID for cattle, as a pour on.
According to the company, Finadyne Transdermal is the world's first non-parasiticide cattle product to be made available as a pour-on.
Dr. Martin Behr, technical manager at MSD Animal Health said: “Finadyne Transdermal is uniquely designed for rapid absorption into the bloodstream and its antipyretic effect has been demonstrated as early as two hours after treatment. This is because innovative penetration enhancers are included in the formulation to improve the absorption of the active ingredient flunixin through the skin.”
The new product comes in pre-calibrated packaging and uses a bottle designed for easy application along an animal’s back.
Dr. Behr added: “It’s much simpler for farmers to treat cattle in this way – as opposed to administering an injection, which can also mean needle-site lesions that can reduce the value of a carcass or compromise hide quality.
“The time taken to handle and treat animals will be much reduced with a transdermal NSAID. There will also be a saving on syringes and needles.”
Finadyne Transdermal (POM-V) is available now from veterinary wholesalers. Further information is available from the MSD Animal Health veterinary support group on 01908 685685.
Fourth year veterinary students from the University of Sydney's Faculty of Veterinary Science have produced a nude calendar in which they use a variety of strategically placed animals to protect their modesty.
The calendar, called Under the Overalls, features a variety of animals, including three lucky (depending on your point of view) llamas, a calf, three sheep and a rather unfortunate fish.
It's all in aid of charity. For more information, visit https://www.facebook.com/undertheoveralls, or you can buy the calendar for $20 at www.undertheoveralls.com.
Picture: House of Cameo
Merck and sanofi-aventis, owners of Merial and Intervet Schering-Plough respectively, have announced that they will not be combining the two animal health businesses as had been planned since March 2010.
In a joint announcement today, the companies said they are discontinuing their agreement primarily because of the increasing complexity of implementing the proposed transaction, both in terms of the nature and extent of the anticipated divestitures and the length of time necessary for the worldwide regulatory review process. The companies agreed that ending their plan is in the best interests of both companies and their respective shareholders, as well as the employees of Merial and Intervet/Schering Plough.
Sanofi-aventis says it remains strongly committed to its animal health activities, which it will continue to develop under the Merial brand as a growth platform of its diversified health business. Merial is one of the world's leading innovation-driven animal healthcare companies dedicated to research, development, manufacturing and commercialization of veterinary pharmaceuticals and vaccines, that generated annual sales of US $ 2.6 billion in 2010.
Merck has also stated its commitment to animal health and Intervet/Schering-Plough, a global leader in the research, development, manufacturing and sale of veterinary medicines which generated sales of US $ 2.9 billion in 2010
As a result of termination, both Merial and Intervet/Schering-Plough will continue to operate independently.
The group is hoping to raise more than £5,000 for the hospital by donating £1 for every pet vaccinated at its West Derby, Gateacre, St Helens and Widnes practices over the next four months.
Sarah Kirkman MRCVS, from White Cross Vets in Gateacre, said: "It’s our job to care for pets, but we also really care about the communities in which we operate, and we have a real affinity with the hospital. This partnership means we’re protecting pets, by vaccinating them against a wide range of nasty diseases, as well as raising money to support the invaluable work that the hospital does."
Allan Eves from Alder Hey Children’s Charity said: "We care for over 275,000 children, young people and their families treating everything from common illnesses to highly complex and specialist conditions. We also lead research into children’s medicines, infection, inflammation and oncology and our charity has raised over £22m to support Alder Hey Children’s Hospital, funding life-saving medical equipment, research and vital facilities. We are so pleased to be working with White Cross Vets on this superb fund-raising initiative and can’t wait to meet the vets and nurses who are helping us."
Sarah added: "We are aiming to raise £5,000, but it could be more. We also want to support the hospital’s therapy dog by providing them with our Complete Wellness Plan for free. The plan provides free health-checks, veterinary care and preventative treatment on an ongoing basis. We already give free membership to several Fire Service Search Dog Teams, as we feel it’s really important to look after these amazing dogs which dedicate their lives to help people."
The charitable campaign is running from the 4th September until the 31st December and plans are also in place for the veterinary surgeons and nurses from White Cross Vets to visit the hospital regularly to talk to the children about pets.
Sarah said: "We give every one of our team four paid donation days a year, so that they can volunteer with a charity of their choice, and we are keen to further our partnership with the hospital by visiting regularly. We already do this in numerous schools across the region and know just how much children love to find out about our day to day roles, and they always have plenty of interesting questions for our nurses and vets to answer."
In mid-September, the Association wrote to the RCVS expressing concern about the August extension to the temporary guidance.
In the latest update from the RCVS, the temporary measure has now been extended to 31 October but the flowchart and guidance have been updated to add some additional steps before a POM-V product can be prescribed remotely.
The BVA says that while it supported the original decision in March as a pragmatic solution and direct response to government restrictions surrounding Covid-19, it is now questioning the ongoing need for such a relaxation in the rules.
In the letter to the RCVS, the BVA also asked for a timeframe for the publication of the results of the RCVS survey of practices’ experiences of remote consulting and prescribing. The Association's own under care working group, chaired by Nigel Gibbens, has been developing a position to respond to the RCVS review.
BVA President James Russell (pictured right) said: "We understand that allowing remote prescription of POM-Vs was a necessary measure at the height of the lockdown, as practices struggled to assess patients in person.
"However, the veterinary professions have done a fantastic job in adapting to the restrictions and are now able to work safely and see patients.
"Whilst we recognise the RCVS has provided additional guidance for the remote prescribing of POM-V, we cannot currently see any reason why a new client would be unable to access in-person veterinary care in the first instance and we are asking RCVS Council to reconsider this measure when it meets in Oct.
"It makes sense to continue allowing vets to remotely prescribe for existing patients, for example if an owner is shielding, but we feel it is no longer appropriate to be remotely prescribing to animals that have never been physically examined by the vet.
“The question of whether we should be able to remotely prescribe POM-V products without first seeing an animal is an important and live debate, and we welcome the resumption of the College’s review. But the longer that temporary measures are in place, the greater the expectation from animal owners that they will always be in place, and the harder it will be to have the discussion about the best way forward.
“As a profession, we are rightly concerned about antimicrobial resistance and we pride ourselves on the responsible use of medicines. Continually extending the temporary measures without a full analysis would risk undermining our position.”
The £11m project, which is backed by Mars Petcare, will include a cutting-edge imaging suite, state-of-the-art treatment facilities and a new linear accelerator.
Plans also include separate cat and dog waiting areas and client walking and comfort areas, seven operating theatres, 15 consultation rooms, recovery suites, lecture halls, a dedicated ICU department and plans for a future hydrotherapy suite.
Daniel Hogan, operations manager at Southfields (pictured right), said: "This is a really exciting time for Southfields and our relocation will provide the region with one of the largest and best-equipped veterinary centres in the UK.
"The team and expertise have grown significantly in the past 18 months. We are very excited to continue to expand the unique and innovative offerings in patient care at our centre.
"Increasing in size will also enable us to provide a dedicated staff wellbeing area and an education centre and lecture hall, which will offer some very exciting qualifications and courses for the wider profession.
"Since our rebranding in 2017, we pride ourselves on leading the industry as a truly multidisciplinary centre with specialists from across the globe, including one of the most illustrious oncology teams in the country. Once this new site is launched, we will be able to offer an even more comprehensive service to our clients and patients."
For more information about Southfields, visit www.southfields.co.uk.
Belfast-based Des Thompson MRCVS was presented with the first ever RCVS Queen's Medal by Her Majesty at Buckingham Palace this afternoon.
Des, pictured right showing off the new medal with his wife Rosalie, received two separate nominations for the medal, both citing his decades of active involvement in veterinary politics which includes being president of the RCVS, the British Small Animal Veterinary Association (BSAVA), the Society of Practising Veterinary Surgeons (SPVS) and the Northern Ireland Veterinary Association, among other organisations.
Also cited was his willingness to help other members of the profession, particularly young vets at the beginning of their careers, through his involvement with organisations such as the Young Vet Network in Northern Ireland and the Veterinary Benevolent Fund.
The Queen's Medal was launched in 2013, with the approval of Her Majesty as Patron of the RCVS, and is now the highest award that can be bestowed upon a veterinary surgeon in recognition of a particularly outstanding contribution to the profession. In receiving the medal, Des was joined by Professor Stuart Reid, current RCVS President, Colonel Neil Smith, immediate past President, and Gordon Hockey, RCVS Registrar.
Des said: "It was a complete honour and a wonderful experience to be received by Her Majesty at Buckingham Palace today, and I'm thrilled to have been awarded the RCVS Queen's Medal. Her Majesty was interested to hear about Northern Ireland, and the fact that I've been practising there since I qualified."
The RCVS has announced that it is to trial a new alternative dispute resolution scheme for users of veterinary services who have complaints which aren't serious enough to call into question a veterinary surgeon or nurse's fitness to practice.
The College says that although it is obliged to investigate all complaints, currently it can only deal with the most serious of complaints raised against a veterinary surgeon's or registered veterinary nurse's fitness to practise. This means that many of the 800 or so complaints received every year by the College's Professional Conduct Department are closed with no further action.
Nick Stace, RCVS Chief Executive Officer and Secretary, said: "It was clear from our consultations last year for the First Rate Regulator initiative that many animal owners who had made complaints were dissatisfied and frustrated with the fact that we were unable to take their, often very legitimate, concerns any further.
"It is for this reason that we decided to launch a trial in order to determine how we could develop an alternative scheme that, through conciliation, would try and resolve these disputes in a way that would be acceptable to both parties.
"Although this trial is small-scale we hope that it will provide the framework for a permanent ADR scheme which I believe would both increase consumer confidence in the profession and help maintain and preserve its reputation.
"We hope that the profession will actively support the trial, and any future scheme, as a way of resolving those intractable disputes which we know can hang over veterinary surgeons and practices and that they recognise that, ultimately, what is good for the consumer can be good for the profession."
The trial will be administered by the Ombudsman Services, an independent and not-for-profit complaint resolution service, and limited to no more than 150 concerns raised about veterinary surgeons in regards to the treatment of a small animal. In most cases concerns referred to the trial will have no arguable case for serious professional misconduct. The trial is free to the users and voluntary, and consent will be sought from both parties before the concern is referred to the Ombudsman Services. The costs of the trial will not exceed £120,000.
Recommendations will be determined through conciliation between both parties and the Ombudsman Services will only be able to suggest, rather than impose, a solution that each party is entitled to accept, or not. Solutions could include, for example, financial accommodation up to the small claims court limit of £10,000 (although the average recommendation is around £100), the issuing of an apology or other practical action to remedy the situation.
The Ombudsman Services will be assisted in its investigations by veterinary advisers who will provide guidance on clinical and other veterinary matters.
The results of the trial, which will end in May 2015, will be presented at the June 2015 meeting of RCVS Council where steps will be considered for the development of a permanent scheme.
More details about the trial can be found at www.rcvs.org.uk/adr
Burgess reminds everyone that RVHD2 is a highly infectious strain of RVHD with few or no visible symptoms. It is fatal and can kill within hours. RVHD2 poses a significant threat to Britain’s rabbit population and outbreaks have been reported all over the UK and Ireland meaning no area is safe.
According to the company, the most recent sales figures show that only 137,405 RVHD2 vaccinations have been distributed in the last year1. This, says the company, shows a concerning number of practices are still not stocking the necessary vaccines to protect rabbits against RVHD2 and other fatal diseases.
Rabbits who have received the combined vaccination for RVHD and myxomatosis need a separate vaccination for RVHD2.
BSAVA President Sue Paterson said: "The British Small Animal Veterinary Association (BSAVA) supports the Rabbit Awareness Week 'Protect and Prevent' approach to saving the lives of rabbits in the UK. The BSAVA urges all rabbit owners to get their rabbits vaccinated against this disease and encourages all practices to remind their clients of the importance of doing this."
Richard Saunders BVSc DZooMed MRCVS said: "It's important for vets to be aware of the importance of vaccinating rabbits against all 3 viral diseases: Myxomatosis, RVHD1 and RVHD2.
"We certainly don't want rabbits to go without their annual myxomatosis vaccine: this horrible disease is very much still around. RVHD1 appears to have been overtaken by the new variant, RVHD2, but should still be vaccinated against.
"RVHD2 is a recent strain of the RVHD virus, which the Nobivac Myxo-RHD vaccine does not cover, and it is, quite literally, everywhere. Transported by inanimate objects as well as animals, it can affect both indoor and outdoor rabbits anywhere in the UK.
"If you wait until you see the first case in your area before recommending vaccination, rabbits will die, when this could be avoided.
"Remember that rabbit owners are much more likely to bury their dead pets at home than cat and especially dog owners, who generally bring their pets to a vet for cremation, and so we, as a profession, are under-aware of the incidence of the disease out there.
"RVHD2 is a core vaccination requirement, being endemic in the UK. Additionally, it’s not just a fatal disease, it’s a fatal disease with a reservoir in the wild. We strongly recommend vaccination of rabbits with either Filavac or Eravac in addition to Nobivac Myxo-RHD."
For more information on this year’s campaign and to request your RAW veterinary pack with marketing materials and free samples, visit www.rabbitawarenessweek.co.uk
Reference
In common with the various other telemedicine platforms which have come to market in recent months, the app will allow veterinary professionals to give help and advice to clients and maintain a revenue stream whilst maintaining social distancing.
VisioCare is highlighting a number of features over and above standard video conferencing, including the ability for the clinician to take photos, video and produce a case file that can be added to the clinical record. The system also allows vets to access the client's smartphone and zoom into areas that need to be examined or turn on a flashlight to improve visibility.
Visiocare says it has also been able to address limitations in clarity due to poor smartphone reception.
Linkyvet includes a payment module - which will be integrated free of charge for orders taken during April - so practices can charge for services provided remotely.
Alexander Arpino, Managing Director of Veterinary Insights, said: "During the current COVID-19 situation, Linkyvet has real potential for triage, as well as enabling routine consultations, without putting anyone at risk. It's good news for patient care, staff wellbeing and also ensuring that the practice remains a viable business that's still there for everyone to return to when life returns to normality.
"Outside crisis times, the tool has ongoing value, providing a great way to generate revenue from services such as advisory consultations and follow ups provided remotely and giving clients a convenient alternative to visiting the practice."
VisioCare Linkyvet is available as a standalone tool or can be included in a bundle with other VisioCare products such as VisioCare Consult, which provides explanatory animations and videos that support clinician recommendations and the myBuddy app, which provides a secure and personalised communication channel between clinic and pet owner.
For more information, visit www.visiocareservices.com or contact your VisioCare Business Development Manager: telephone 01403 800135 or email enquiries@visiocareservices.com.
Pfizer Animal Health has launched Poulvac, the first modified live vaccine against E.coli in chickens.
The company claims that the vaccine, which can be used from one day of age, is set to bring major benefits in safeguarding the health of broilers, pullets for egg laying and breeding stock.
According to Pfizer, E.coli is one of the most significant bacterial pathogens found in chicks during the first week, leading to problems throughout the life of a flock including inferior performance, lack of uniformity and increased mortality. It is a costly, widespread problem for the UK poultry industry.
The vaccine was developed from research beginning in the 1990s at the Government's veterinary laboratories at Weybridge (now AHVLA) in the UK, employing genome technology to produce an avirulent strain of E.coli that induces protective immunity to the pathogenic strains of the bacteria.
The vaccine is completely non-pathogenic, and does not persist in the bird or the environment for any significant period of time. A gene deletion in its development restricts in vivo replication and leaves behind activated macrophages ready to respond to pathogenic E.coli strains.
Dr Stuart Andrews, poultry technical manager of Pfizer in the UK and Ireland said: "Poulvac E. coli provides broad cross protection against the key serotypes of E. coli infecting chickens. It is the only modified live, nonreactive vaccine proven to meet the European regulatory requirements for efficacy and safety.
"Trials have confirmed that Poulvac E.coli does not persist in the bird and proves to be self-limiting. The vaccine can survive in the environment for only a short time, and spread to in-contact birds is also limited."
The vaccine is administered as a coarse spray with onset of immunity 14 days afterwards and duration of immunity for up to 12 weeks. It can be used from day-old up to six weeks before the onset of lay, and has a nil day withdrawal period.
In the USA where Poulvac E coli has been available for six years field experience has shown the considerable benefits. In the Midwest where average layer mortality at 50 weeks of age was 2.31 per cent, this was reduced to 1.51 per cent with three doses of the vaccine*. In Eastern USA flock mortality compared with five previous flocks was reduced from over three per cent to one per cent.
A field trial in the USA with more than 300,000 broiler breeders vaccination before lay reduced mortality from 2.8 to 1.9 per cent - with only two out of 28 flocks needing antibiotic treatment compared with 13 of the 28 unvaccinated flocks.
On a broiler field trial in Georgia over four million birds were vaccinated with Poulvac E. coli at hatch. The vaccinated birds had a better feed conversion (1.79 against 1.84 for the controls) and with condemnations at the processing plant down from 1.22 to 0.73 per cent the result was a lower production cost of 0.51¢ per lb.
In another broiler trial covering more than two million birds in Arkansas livability was improved from 95.20 to 95.77 per cent and feed conversion improved from 1.95 to 1.90, gaining 0.45¢ per lb.
* Pfizer says it is important to note that in these studies carried out in the USA more than one dose of the vaccine was often administered. A single vaccination is licensed in the Summary of Product Characteristics however, where clinical disease requires and at the discretion of a veterinary surgeon, the vaccination schedule may be re-started as there is no contra-indication on the SPC.